Skip to main content
. 2023 May 3;20(5):369–384. doi: 10.20892/j.issn.2095-3941.2023.0046

Figure 3.

Figure 3

Strategies for targeting the sialylated glycan-SIGLEC axis. (1) Liposomal nanoparticles coated with high affinity ligands deliver anti-tumor drugs to lymphoma cells, which express SIGLEC2 or SIGLEC3. (2) Antibody-sialidase conjugates destroy the sialic acids on tumor cells and release the SIGLEC receptors. (3) Anti-SIGLEC antibodies block the specific sialoside-SIGLEC axis. (4) Antibody-drug conjugates target and are endocytosed into tumor cells by SIGLECs. (5) Sialyltransferase inhibitors decrease sialyltransferase expression. (6) SIGLEC-specific CAR-T increases the cytotoxicity of immune cells.